Skip to main content
Top
Published in: Current Rheumatology Reports 3/2012

Open Access 01-06-2012 | OSTEOPOROSIS AND METABOLIC BONE DISEASE (KG SAAG, SECTION EDITOR)

Inflammatory Rheumatic Disorders and Bone

Authors: Irene E. M. Bultink, Marijn Vis, Irene E. van der Horst-Bruinsma, Willem F. Lems

Published in: Current Rheumatology Reports | Issue 3/2012

Login to get access

Abstract

Inflammatory joint diseases such as rheumatoid arthritis, as well as other rheumatic conditions, such as systemic lupus erythematosus (SLE) and ankylosing spondylitis, comprise a heterogeneous group of joint disorders that are all associated with extra-articular side effects, including bone loss and fractures. The concept of osteoimmunology is based on growing insights into the links between the immune system and bone. The pathogenesis of osteoporosis in these patients is multifactorial. We have, more or less as an example, described this extensively for patients with SLE. High disease activity (inflammation) and immobility are common factors that substantially increase fracture risk in these patients, on top of the background fracture risk based on, among other factors, age, body mass index, and gender. Although no fracture reduction has been shown in intervention studies in patients with inflammatory rheumatic diseases, we present treatment options that might be useful for clinicians who are treating these patients.
Literature
1.
go back to reference Kalla AA, Fataar AB, Jessop SJ, et al. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum. 1993;36:1726–34.PubMedCrossRef Kalla AA, Fataar AB, Jessop SJ, et al. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum. 1993;36:1726–34.PubMedCrossRef
2.
go back to reference Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14:106–12.PubMedCrossRef Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14:106–12.PubMedCrossRef
3.
go back to reference Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol. 2003;22:318–23.PubMedCrossRef Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol. 2003;22:318–23.PubMedCrossRef
4.
go back to reference Uaratanawong S, Deesomchoke U, Lertmaharit S, et al. Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol. 2003;30:2365–8.PubMed Uaratanawong S, Deesomchoke U, Lertmaharit S, et al. Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol. 2003;30:2365–8.PubMed
5.
go back to reference • Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res. 2012;1:2–8. This is an outstanding overview on the multifactorial pathogenesis of osteoporosis and fractures in SLE.CrossRef • Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res. 2012;1:2–8. This is an outstanding overview on the multifactorial pathogenesis of osteoporosis and fractures in SLE.CrossRef
6.
go back to reference Almehed K, Forsblad DH, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients: extended report. Rheumatology (Oxford). 2007;46:1185–90.CrossRef Almehed K, Forsblad DH, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients: extended report. Rheumatology (Oxford). 2007;46:1185–90.CrossRef
7.
go back to reference Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res. 1995;8:137–45.PubMedCrossRef Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res. 1995;8:137–45.PubMedCrossRef
8.
go back to reference Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;54:2044–50.CrossRef Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;54:2044–50.CrossRef
9.
go back to reference Lakshminarayanan S, Walsh S, Mohanraj M, et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102–8.PubMed Lakshminarayanan S, Walsh S, Mohanraj M, et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102–8.PubMed
10.
go back to reference Yee CS, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:111–3.PubMedCrossRef Yee CS, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:111–3.PubMedCrossRef
11.
go back to reference Lee C, Almagor O, Dunlop DD, et al. Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus. Arthritis Rheum. 2007;57:585–92.PubMedCrossRef Lee C, Almagor O, Dunlop DD, et al. Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus. Arthritis Rheum. 2007;57:585–92.PubMedCrossRef
12.
go back to reference Fangtham M, Petri M. Predictors of osteoporotic fracture in SLE [abstract]. Arthritis Rheum. 2009;60(Suppl):S110. Fangtham M, Petri M. Predictors of osteoporotic fracture in SLE [abstract]. Arthritis Rheum. 2009;60(Suppl):S110.
13.
go back to reference Svenungsson E, Fei GZ, Jensen-Urstad K, et al. TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus. 2003;12:454–61.PubMedCrossRef Svenungsson E, Fei GZ, Jensen-Urstad K, et al. TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus. 2003;12:454–61.PubMedCrossRef
14.
go back to reference Frostegard J, Svenungsson E, Wu R, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 2005;52:192–200.PubMedCrossRef Frostegard J, Svenungsson E, Wu R, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 2005;52:192–200.PubMedCrossRef
15.
go back to reference Moerman EJ, Teng K, Lipschitz DA, et al. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell. 2004;3:379–89.PubMedCrossRef Moerman EJ, Teng K, Lipschitz DA, et al. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell. 2004;3:379–89.PubMedCrossRef
16.
go back to reference Teichmann J, Lange U, Stracke H, et al. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int. 1999;18:137–40.PubMedCrossRef Teichmann J, Lange U, Stracke H, et al. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int. 1999;18:137–40.PubMedCrossRef
17.
go back to reference Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol. 2009;28:579–85.PubMedCrossRef Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol. 2009;28:579–85.PubMedCrossRef
18.
go back to reference Lee C, Almagor O, Dunlop DD, et al. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford). 2006;45:53–60.CrossRef Lee C, Almagor O, Dunlop DD, et al. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford). 2006;45:53–60.CrossRef
19.
go back to reference Borba VZ, Vieira JG, Kasamatsu T, et al. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int. 2009;20:427–33.PubMedCrossRef Borba VZ, Vieira JG, Kasamatsu T, et al. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int. 2009;20:427–33.PubMedCrossRef
20.
go back to reference Huisman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol. 2001;28:2535–9.PubMed Huisman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol. 2001;28:2535–9.PubMed
21.
go back to reference Toloza SM, Cole DE, Gladman DD, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010;19:13–9.PubMedCrossRef Toloza SM, Cole DE, Gladman DD, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010;19:13–9.PubMedCrossRef
22.
go back to reference Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008;47:920–3.CrossRef Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008;47:920–3.CrossRef
23.
go back to reference Formiga F, Moga I, Nolla JM, et al. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol. 1997;15:387–92.PubMed Formiga F, Moga I, Nolla JM, et al. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol. 1997;15:387–92.PubMed
24.
go back to reference Jardinet D, Lefebvre C, Depresseux G, et al. Longitudinal analysis of bone mineral density in premenopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford). 2000;39:389–92.CrossRef Jardinet D, Lefebvre C, Depresseux G, et al. Longitudinal analysis of bone mineral density in premenopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford). 2000;39:389–92.CrossRef
25.
go back to reference Kipen Y, Briganti E, Strauss B, et al. Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol. 1999;26:310–7.PubMed Kipen Y, Briganti E, Strauss B, et al. Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol. 1999;26:310–7.PubMed
26.
go back to reference Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999;42:882–90.PubMedCrossRef Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999;42:882–90.PubMedCrossRef
27.
go back to reference Lee C, Almagor O, Dunlop DD, et al. Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol. 2007;34:2018–23.PubMed Lee C, Almagor O, Dunlop DD, et al. Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol. 2007;34:2018–23.PubMed
28.
go back to reference Li EK, Tam LS, Griffith JF, et al. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol. 2009;36:1646–52.PubMedCrossRef Li EK, Tam LS, Griffith JF, et al. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol. 2009;36:1646–52.PubMedCrossRef
29.
go back to reference Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Review. Nat Rev Rheumatol. 2009;5:667–76.PubMedCrossRef Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Review. Nat Rev Rheumatol. 2009;5:667–76.PubMedCrossRef
30.
go back to reference Lacey DL, Timms, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.PubMedCrossRef Lacey DL, Timms, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.PubMedCrossRef
31.
go back to reference • Geusens PP, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res Ther. 2011;13(5):242. Epub. This is a large overview on osteoimmunology in rheumatic diseases.PubMedCrossRef • Geusens PP, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res Ther. 2011;13(5):242. Epub. This is a large overview on osteoimmunology in rheumatic diseases.PubMedCrossRef
32.
go back to reference •• Schett G, Saag KG, Bijlsma JWJ. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1415–9. This is an outstanding state-of-the-art article on bone biology.PubMedCrossRef •• Schett G, Saag KG, Bijlsma JWJ. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1415–9. This is an outstanding state-of-the-art article on bone biology.PubMedCrossRef
33.
go back to reference Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in RA. Arthritis Rheum. 2008;58:1299–309.PubMedCrossRef Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in RA. Arthritis Rheum. 2008;58:1299–309.PubMedCrossRef
34.
35.
go back to reference Lories RJ, Luyten FP. Osteoimmunology: Wnt antagonists: for better or worse? Nat Rev Rheumatol. 2009;5:420–1.PubMedCrossRef Lories RJ, Luyten FP. Osteoimmunology: Wnt antagonists: for better or worse? Nat Rev Rheumatol. 2009;5:420–1.PubMedCrossRef
36.
go back to reference Garnero P, Tabassi NC, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol. 2008;35:2313–5.PubMedCrossRef Garnero P, Tabassi NC, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol. 2008;35:2313–5.PubMedCrossRef
37.
go back to reference Terpos E, Fragidaki K, Konsta M, et al. Early effects of Il-6 receptor inhibition on bone homeostasis. Clin Exp Rheumatol. 2011;29:921–5.PubMed Terpos E, Fragidaki K, Konsta M, et al. Early effects of Il-6 receptor inhibition on bone homeostasis. Clin Exp Rheumatol. 2011;29:921–5.PubMed
38.
go back to reference Xu S, Wang Y, Lu J, Xu. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int. 2011. Xu S, Wang Y, Lu J, Xu. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int. 2011.
39.
go back to reference Schett G, Stach C, Zwerina J, et al. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008;58:2936–48.PubMedCrossRef Schett G, Stach C, Zwerina J, et al. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008;58:2936–48.PubMedCrossRef
40.
go back to reference Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:522–30.PubMedCrossRef Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:522–30.PubMedCrossRef
41.
go back to reference Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 1994;8914:23–7.CrossRef Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 1994;8914:23–7.CrossRef
42.
go back to reference Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with Infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495–9.PubMedCrossRef Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with Infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495–9.PubMedCrossRef
43.
go back to reference Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YP, et al. Changes in hand and generalized bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:330–6.PubMedCrossRef Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YP, et al. Changes in hand and generalized bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:330–6.PubMedCrossRef
44.
go back to reference Dirven L, Güler-Yüksel M, de Beus WM, et al. Changes in hand bone mineral density and the association with the level of disease activity in patients with RA. Arthritis Care Res. 2011:1691–9. Dirven L, Güler-Yüksel M, de Beus WM, et al. Changes in hand bone mineral density and the association with the level of disease activity in patients with RA. Arthritis Care Res. 2011:1691–9.
45.
go back to reference Spector TD, Hall GM, McCloskey EV, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ. 1993;306:558.PubMedCrossRef Spector TD, Hall GM, McCloskey EV, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ. 1993;306:558.PubMedCrossRef
46.
go back to reference Huusko TM, Korpela M, Karppi P, et al. Threefold increased risk of hip fractures with rheumatoid arthritis in central Finland. Ann Rheum Dis. 2001;60:521–2.PubMedCrossRef Huusko TM, Korpela M, Karppi P, et al. Threefold increased risk of hip fractures with rheumatoid arthritis in central Finland. Ann Rheum Dis. 2001;60:521–2.PubMedCrossRef
47.
go back to reference van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–12.12.PubMedCrossRef van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–12.12.PubMedCrossRef
48.
go back to reference •• Roux C. Osteoporosis in inflammatory joint diseases. Osteoporosis Int. 2011;22:412–23. This is an elegant overview, predominantly on clinical data regarding osteoporosis and rheumatic diseases. •• Roux C. Osteoporosis in inflammatory joint diseases. Osteoporosis Int. 2011;22:412–23. This is an elegant overview, predominantly on clinical data regarding osteoporosis and rheumatic diseases.
49.
go back to reference Vis M, Haavardsholm EA, Bøyesen P, et al. High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int. 2011;22:2413–9.PubMedCrossRef Vis M, Haavardsholm EA, Bøyesen P, et al. High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int. 2011;22:2413–9.PubMedCrossRef
50.
go back to reference S. Amin, S. Gabriel, S. Achenbach et al. Fracture risk is increased in young women with rheumatoid arthritis. J Bone Miner Res. 2011;26(Suppl 1). S. Amin, S. Gabriel, S. Achenbach et al. Fracture risk is increased in young women with rheumatoid arthritis. J Bone Miner Res. 2011;26(Suppl 1).
51.
go back to reference Cooper C, Carbone L, Michet CJ, et al. Fracture risk in patients with AS: a population based study. J Rheumatol. 1994;10:1887–82. Cooper C, Carbone L, Michet CJ, et al. Fracture risk in patients with AS: a population based study. J Rheumatol. 1994;10:1887–82.
52.
go back to reference Vosse D, Landewé R, van der Heijde D, et al. AS and the risk of fracture: results from a large primary care based nested case–control study. Ann Rheum Dis. 2009;68:1839–42.PubMedCrossRef Vosse D, Landewé R, van der Heijde D, et al. AS and the risk of fracture: results from a large primary care based nested case–control study. Ann Rheum Dis. 2009;68:1839–42.PubMedCrossRef
53.
go back to reference Vosse D, Feldtkeller E, Erlendsson, et al. Clinical vertebral fractures in patients with AS. J Rheumatol. 2004;10:1981–5. Vosse D, Feldtkeller E, Erlendsson, et al. Clinical vertebral fractures in patients with AS. J Rheumatol. 2004;10:1981–5.
54.
go back to reference Franck H, Meurer T, Hofbauer LC, et al. Evaluation of BMD, hormones, biochemical markers of bone metabolism, and OPG serum levels in patients with AS. Rheumatol. 2004;31:2236–41. Franck H, Meurer T, Hofbauer LC, et al. Evaluation of BMD, hormones, biochemical markers of bone metabolism, and OPG serum levels in patients with AS. Rheumatol. 2004;31:2236–41.
55.
go back to reference Arends SA, Spoorenberg A, Bruyn GA, et al. The relationship between BMD, vitamin D levels and bone markers in AS patients. Osteoporos Int. 2011;22:1431–9.PubMedCrossRef Arends SA, Spoorenberg A, Bruyn GA, et al. The relationship between BMD, vitamin D levels and bone markers in AS patients. Osteoporos Int. 2011;22:1431–9.PubMedCrossRef
56.
go back to reference Lee YS, Schlotzhauer T, Ott SM, et al. Skeletal status of men with early and late AS. Am J Med. 1997;103:233–41.PubMedCrossRef Lee YS, Schlotzhauer T, Ott SM, et al. Skeletal status of men with early and late AS. Am J Med. 1997;103:233–41.PubMedCrossRef
57.
go back to reference Karberg K, Zochling J, Sieper J, et al. Bone loss is detected more frequently in patients with AS with syndesmophytes. J Rheumatol. 2005;32:1290–8.PubMed Karberg K, Zochling J, Sieper J, et al. Bone loss is detected more frequently in patients with AS with syndesmophytes. J Rheumatol. 2005;32:1290–8.PubMed
58.
go back to reference van der Weijden MA, van Denderen JC, Lems WF, et al. Low BMD is related to male gender and decreased functional capacity in early AS. Clin Rheumatol. 2011;30:497–503.PubMedCrossRef van der Weijden MA, van Denderen JC, Lems WF, et al. Low BMD is related to male gender and decreased functional capacity in early AS. Clin Rheumatol. 2011;30:497–503.PubMedCrossRef
59.
go back to reference van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, et al. High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int. 2011; Epub. van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, et al. High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int. 2011; Epub.
60.
go back to reference Allali F, Breban M, Porcher R, et al. Increase in BMD of patients with AS treated with anti-TNF. Ann Rheum Dis. 2003;62:347–9.PubMedCrossRef Allali F, Breban M, Porcher R, et al. Increase in BMD of patients with AS treated with anti-TNF. Ann Rheum Dis. 2003;62:347–9.PubMedCrossRef
61.
go back to reference Maksymowych WP, Chiochanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on MRI predict the development of new syndesmophytes in AS. Arthritis Rheum. 2009;60:93–102.PubMedCrossRef Maksymowych WP, Chiochanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on MRI predict the development of new syndesmophytes in AS. Arthritis Rheum. 2009;60:93–102.PubMedCrossRef
62.
go back to reference Schett G, Independent development of inflammation and new bone formation in ankylosing spondylitis. Arthritis Rheum. 2012, Epub. Schett G, Independent development of inflammation and new bone formation in ankylosing spondylitis. Arthritis Rheum. 2012, Epub.
63.
go back to reference Zhang J, Saag KG, Curtis JR. Longterm safety concerns of antiresorptive therapy. Rheum Dis Clin North America. 2011;37:387–400.CrossRef Zhang J, Saag KG, Curtis JR. Longterm safety concerns of antiresorptive therapy. Rheum Dis Clin North America. 2011;37:387–400.CrossRef
64.
go back to reference Patlas N, Colomb G, Yaffe P, et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60:68–73.PubMedCrossRef Patlas N, Colomb G, Yaffe P, et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60:68–73.PubMedCrossRef
65.
go back to reference Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for longterm treatment of glucocorticoid induced osteoporosis. Arthritis Rheum. 2011;63:325–8.PubMedCrossRef Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for longterm treatment of glucocorticoid induced osteoporosis. Arthritis Rheum. 2011;63:325–8.PubMedCrossRef
Metadata
Title
Inflammatory Rheumatic Disorders and Bone
Authors
Irene E. M. Bultink
Marijn Vis
Irene E. van der Horst-Bruinsma
Willem F. Lems
Publication date
01-06-2012
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 3/2012
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-012-0252-8

Other articles of this Issue 3/2012

Current Rheumatology Reports 3/2012 Go to the issue

OSTEOPOROSIS AND METABOLIC BONE DISEASE (KG SAAG, SECTION EDITOR)

Bone Loss in Rheumatoid Arthritis: Systemic, Periarticular, and Focal

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Interleukin-17 in Inflammatory Myopathies

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Animal Models of Inflammatory Myopathy

OSTEOPOROSIS AND METABOLIC BONE DISEASE (KG SAAG, SECTION EDITOR)

Bone and Kidney Disease: Diagnostic and Therapeutic Implications

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine